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Abstract
Background: Development of antiviral drugs that have broad-spectrum activity against a number of viral infections would
be of significant benefit. Due to the evolution of resistance to currently licensed antiviral drugs, development of novel anti-
influenza drugs is in progress, including Favipiravir (T-705), which is currently in human clinical trials. T-705 displays broad-
spectrum in vitro activity against a number of viruses, including Rift Valley Fever virus (RVFV). RVF is an important neglected
tropical disease that causes human, agricultural, and economic losses in endemic regions. RVF has the capacity to emerge in
new locations and also presents a potential bioterrorism threat. In the current study, the in vivo efficacy of T-705 was
evaluated in Wistar-Furth rats infected with the virulent ZH501 strain of RVFV by the aerosol route.
Methodology/Principal Findings: Wistar-Furth rats are highly susceptible to a rapidly lethal disease after parenteral or
inhalational exposure to the pathogenic ZH501 strain of RVFV. In the current study, two experiments were performed: a
dose-determination study and a delayed-treatment study. In both experiments, all untreated control rats succumbed to
disease. Out of 72 total rats infected with RVFV and treated with T-705, only 6 succumbed to disease. The remaining 66 rats
(92%) survived lethal infection with no significant weight loss or fever. The 6 treated rats that succumbed survived
significantly longer before succumbing to encephalitic disease.
Conclusions/Significance: Currently, there are no licensed antiviral drugs for treating RVF. Here, T-705 showed remarkable
efficacy in a highly lethal rat model of Rift Valley Fever, even when given up to 48 hours post-infection. This is the first study
to show protection of rats infected with the pathogenic ZH501 strain of RVFV. Our data suggest that T-705 has potential to
be a broad-spectrum antiviral drug.
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Introduction
Food and Drug Administration (FDA)-licensed antiviral drugs
generally target one virus or a small group of closely-related viruses.
Development of a broad-spectrum antiviral drug that could treat a
range of different viral infections would be useful, especially if the
drug acts against emerging viruses or those that could be used as a
bioweapon. Successful antiviral drugs have been licensed to treat
human influenza, but these antiviral drugs generally utilize an
influenza-specific mechanism and therefore are not applicable to
other viral infections. An important limitation of the currently
licensed influenza drugs is that the virus evolves resistance easily [1,2].
Favipiravir (or T-705) is a novel antiviral drug that is presently
in clinical trials to treat human influenza [3–5]. It has a unique
action among anti-influenza drugs in that it directly inhibits the
viral RNA polymerase, but not cellular DNA or RNA polymerases
[6,7]. T-705 has shown in vitro and some in vivo inhibitory effects on
a variety of pathogenic RNA viruses (examples include: Junin, Rift
Valley Fever, Yellow Fever, West Nile, Western equine enceph-
alitis, foot-and-mouth disease virus, and norovirus) [8–18]. These
results are promising and exemplify the potential usefulness of T-
705 as a broad-spectrum therapeutic.
Rift Valley Fever (RVF) is a globally-relevant, emerging disease
in both livestock and humans in Africa and the Middle East, and
outbreaks lead to millions of dollars of losses in human and
economic terms in the affected areas [19,20]. Due to the
widespread range of the insect vectors, RVF virus (RVFV) has
the potential to spread to Europe and the Americas [21–26],
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which would cause considerable economic damage and human
morbidity and mortality. Although RVFV is a mosquito-borne
virus, humans are largely exposed via contact or inhalation from
contaminated animal carcasses. Aerosol exposure represents both
a natural route of infection, and is also a route of concern for use of
RVFV as a biological weapon. Therefore, evaluation of medical
countermeasures against an aerosol exposure is an important
component of pre-clinical studies.
There are currently no approved vaccines or therapeutics for
preventing or treating RVF in either humans or ruminants. RVFV
is listed as a Category A priority pathogen according to the
National Institutes of Allergy and Infectious Diseases (NIAID) and
is thus considered a potential bioterror threat due to the ease of
transmission by inhalation [27]. It is regulated as an overlap Select
Agent by the Centers for Disease Control (CDC) and U.S.
Department of Agriculture (USDA) [28,29] and requires biosafety
level (BSL) -3 containment for laboratory and animal work with
virulent isolates such as ZH501 [30].
Previous studies on the in vitro and in vivo efficacy of T-705
against RVFV have utilized either the MP-12 vaccine strain or the
closely-related Punta Toro virus (both can be handled at BSL-2) as
surrogates for wild-type BSL-3 strains of RVFV [9,10]. In these
previous studies, T-705 treatment showed in vitro activity against
both viruses, as well as enhanced survival in mice and hamsters
infected with Punta Toro virus.
Here, we evaluate the ability of T-705 to treat rats infected with
the lethal and pathogenic ZH501 strain of RVFV. For this study,
we utilize the Wistar-Furth rat model of inhalational Rift Valley
Fever [31]. In this model, Wistar-Furth rats exposed to RVFV by
aerosol develop a fulminant hepatic disease and succumb within
4–6 days post-infection. The median lethal dose (LD50) of
aerosolized ZH501 RVFV in Wistar-Furth rats is 2 plaque-
forming units (pfu), further emphasizing the sensitivity of this
model. In this study, T-705 showed remarkable efficacy, with 92%
of treated rats surviving lethal infection, even when T-705 was
administered as late as 48 hours post-infection. This study
provides important preclinical proof-of-concept data and demon-
strates that T-705 is efficacious in a stringent rat model of lethal
RVF. These findings support the broad-spectrum applicability of
T-705 to treat pathogenic viral agents other than influenza.
Materials and Methods
Ethics statement
All animal work described here was carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health and the Animal Welfare Act. The protocol was approved
by the University of Pittsburgh Institutional Animal Care and Use
Committee (Assurance Number A3187-01). The protocol was also
approved by the Animal Care and Use Review Office of the US
Army Medical Research and Materiel Command under protocol
CB-2010-95.05. This work complies with Department of Defense
(DoD) Instruction 3216.01 (Use of Animals in DoD Programs) and
US Army Regulation 40-33 (The Care and Use of Laboratory
Animals in DoD Programs).
Biosafety information
All work with live RVFV was conducted at BSL-3 in the
University of Pittsburgh Regional Biocontainment Laboratory
(RBL). For respiratory protection, all personnel wore powered air
purifying respirators (PAPRs) (either the 3M GVP-1 PAPR with L-
series bumpcap, or 3M TR-3000 PAPR with 3M Versaflo M-
Series headgear) or used a class III biological safety cabinet. All
animals were housed in individually-ventilated micro-isolator
caging (Allentown, Inc, Allentown, NJ). Vesphene II se (1:128
dilution, Steris Corporation, Erie, PA) was used to disinfect all
liquid wastes and surfaces associated with the agent. All solid
wastes, used caging, and animal wastes, were steam-sterilized.
Animal carcasses were digested via alkaline hydrolysis (Peerless
Waste Solutions, Holland, MI). The University of Pittsburgh
Regional Biocontainment Laboratory is a Registered Entity with
the CDC/USDA for work with Rift Valley Fever.
Virus propagation and culture
RVFV strain ZH501 was kindly provided by Barry Miller
(CDC, Ft. Collins, CO) and Stuart Nichol (CDC, Atlanta). Prior to
receipt, the virus was generated from reverse genetics plasmids
[32] containing the wild-type ZH501 sequence, which was
confirmed by sequencing. Virus was propagated on VeroE6 cells
using standard methods. For virus quantitation, standard plaque
assays were performed using an agarose overlay (16 minimum
essential medium, 2% FBS, 1% penicillin/streptomycin, HEPES
buffer, and 0.8% SeaKem agarose), incubated for 3 days at 37uC,
and visualized using crystal violet. For titration of tissue samples,
tissue pieces were homogenized in 26 volume of DMEM+10%
FBS using an Omni tissue homogenizer (Omni International),
followed by a standard plaque assay on the homogenate.
Animal studies
Female Wistar-Furth rats (WF/NHsd; 8 to 10 weeks old) were
obtained from Harlan Laboratories. All animals were provided
rodent food (IsoPro Rodent 3000) and water ad libitum. All
rats had implantable, programmable temperature transponders
(IPTT-300; Bio Medic Data Systems, Seaford, DE) inserted
subcutaneously between the shoulder blades for identification and
temperature monitoring. Rats were exposed to RVFV as described
below. Body temperature and weight were recorded daily starting
4 days prior to infection, and each animal was monitored at least
twice daily for the development of clinical signs, including
hunched posture, ruffled fur, decreased activity or response to
stimuli, or neurological signs (head tilt and circling or rolling in
cage). Rats meeting endpoint criteria as defined in the IACUC
protocol we euthanized. Endpoint criteria vary depending upon
the strain of rat infected with RVFV. For Wistar-Furth rats, which
are very sensitive to RVFV, endpoint criteria include two or more
of the following: body temperature of .39uC or ,36uC,
porphyrin staining around the eyes/nose/mouth, unresponsive
to stimuli, or .5% weight loss for more than 2 consecutive days.
Any rats that survives beyond 6 days post-infection and that also
displays neurological signs (head tilt, tremors, circling or rolling in
cage) along with weight loss (.5%) or temperature variations (.
Author Summary
Broad-spectrum antiviral drugs are preferred because they
have the capacity to treat a range of viral illnesses rather
than just one. Food and Drug Administration (FDA)
approval of antiviral drugs to treat neglected tropical
diseases is difficult to obtain due to ethical and logistical
considerations when conducting human clinical trials. Rift
Valley Fever (RVF) is an endemic tropical disease that
causes human morbidity and mortality, as well as
economic damage to the livestock industry. There are no
licensed antiviral drugs to treat RVF. In this study, we
found that a novel anti-influenza drug, Favipiravir (T-705),
is able to prevent lethal RVF in rats, and therefore shows
promise as a broad-spectrum antiviral treatment.
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39uC or ,36uC) also qualify for euthanasia. Blood was drawn
by cardiac puncture immediately prior to euthanasia. During
necropsy, a portion of each tissue was frozen for determination of
viral load by plaque assay, and a second piece of each tissue was
fixed in 10% neutral buffered formalin for 2 weeks prior to
removal from the BSL-3 facility. Fixed tissues were processed for
histology as described [33]. The pathologist was blinded when
scoring samples for the degree of pathological changes.
Aerosol exposures
Inside a Class III biosafety cabinet, rats were exposed for
10 minutes in a whole-body aerosol chamber to small-particle
aerosols created by a 3-jet Collison nebulizer (BGI, Inc., Waltham,
MA) controlled by the AeroMP aerosol exposure control system
(Biaera Technologies, Hagerstown, MD). Air sampling and dose
calculation were done as previously described [31].
T-705 drug treatment
Favipiravir (T-705) was supplied by Toyama Chemical Com-
pany (Tokyo, Japan). Suspensions of T-705 were made using a
mortar and pestle followed by dilution to the desired concentration
in 0.4% carboxymethylcellulose (CMC) and 10% sucrose.
Untreated control rats were given 0.4% CMC and 10% sucrose
as a vehicle control. T-705 was administered orally to rats using a
1 ml syringe in a volume of 200 ul. While wearing bite-resistant
gloves, rats were picked up and restrained by scruffing. The
syringe was then inserted into the mouth towards the cheek, and
the drug suspension was slowly ejected. All rats complied with
drug administration.
Indirect IgG ELISA
96-well plates were coated with RVFV MP-12-infected inacti-
vated lysate (diluted 1:20 in DPBS) and incubated overnight at
4uC. Plates were washed 3 times, followed by the addition of
control or test sera (diluted 1:100–1:6400, four-fold, in blocking
buffer) in duplicate. After incubation at 37uC for 1 hour, the plates
were washed 3 times, followed by the addition of horseradish
peroxidase-conjugated goat anti-rat IgG (H+L, KPL, Inc.,
Gaithersburg, MD) diluted 1:2000 in blocking buffer. The
secondary antibody was incubated for 1 hour at 37uC, washed 3
times, and 2,29-azinodiethylbenzothiazoline sulfonic acid (ABTS)
substrate (KPL, Inc.) was added to each well. Plates were
incubated in the dark at 37uC for 30 minutes. After that time,
100 mL of ABTS stop solution was added to the wells and the
optical density (OD) was determined at 405 nm. The SumOD was
determined by subtracting the blank value from all wells, then
summing the average ODs from each dilution (1:100, 1:400,
1:1600, 1:6400) for each sample.
Statistical analyses
Statistics were performed using GraphPad Prism Software.
Nonparametric logrank tests (Mantel-Cox) was used to compare
survival distribution between T-705-treated groups and untreated
control animals. Unpaired t-tests were used to compare the mean
time to death (MTD) of treated and untreated groups of rats.
Significance of ELISA results was determined by unpaired t-tests
comparing each treated group with the untreated control group.
Asterisks indicate significance as follows: **** = p,0.0001;
*** = 0.0001,p,0.001; ** = 0.001,p,0.01; * = 0.01,p,0.05.
Results
Wistar-Furth rats have historically been the most commonly
used rat strain for studying RVF virus infections due to their rapid
development of fulminant hepatitis after exposure to small doses of
the pathogenic ZH501 strain [31,32,34–36]. The LD50 of RVFV
ZH501 in Wistar-Furth rats is approximately 2 pfu for both
subcutaneous and aerosol exposure [31,37]. Death of Wistar-
Furth rats occurs within 4–6 days after aerosol exposure.
Moribund Wistar-Furth rats have high levels of infectious virus
throughout a wide range of peripheral tissues (liver, lung, spleen,
brain, heart, kidney), with the highest levels of virus replication
occurring in the spleen and liver (108 to 109 pfu/g) [31]. Wistar-
Furth rats typically do not display clinical signs until the last
24 hours before death, when a short febrile response, minimal
weight loss, and porphyrin staining around the eyes/nose/mouth
are hallmarks of end-stage disease.
Because they develop a precipitously lethal disease at a very low
dose, Wistar-Furth rats represent a very stringent model in which
to test potential vaccine and therapeutic candidates. They further
serve as a relevant model of the acute hepatic/hemorrhagic
disease seen in a subset of humans infected with RVFV [31,38–
40]. This study evaluated the effectiveness of T-705 to prevent
illness and death in Wistar-Furth rats infected with the virulent
ZH501 strain of RVF virus by inhalational exposure. Efficacy was
evaluated in two experiments: a dose-determination study and a
delayed-treatment study.
T-705 dose-determination study
The dose range of T-705 used in human clinical trials for
treatment of influenza infection is between 50–100 mg/kg given
orally twice or three times a day. Based on this, doses of 20, 50,
and 100 mg/kg were administered to Wistar-Furth rats twice daily
(BID) by the oral route following infection with RVFV. In the
initial study, all rats received an average of 50 pfu of the virulent
recombinant RVFV strain ZH501 during the aerosol exposure,
which is approximately 25 LD50 [31]. At this challenge dose, all of
the untreated control rats succumbed to infection within 4–6 days
as expected (Fig. 1A). For the rats treated with T-705, the first dose
was administered within 1 hour post-infection (hpi), and then
treatment was continued twice daily for 14 days. After the end of
treatment, the rats were monitored for survival for another 28
days.
Regardless of dose, T-705 treatment significantly prolonged
survival of Wistar-Furth rats after RVFV challenge (Fig. 1A; p,
0.0001 by Log-Rank test for each treated group compared to
untreated controls). Two rats (out of 12) succumbed in the 20 mg/
kg group, one rat (out of 12) succumbed in the 50 mg/kg group,
and all rats given 100 mg/kg of T-705 survived. Of the three T-
705 treated rats that succumbed, the mean time to death (MTD)
was significantly longer than the untreated controls (7.5+/20.5
days compared to 4.6+/20.3 days, respectively; p = 0.0001 by
unpaired t-test). Survival times were not significantly different
between the groups that received T-705 as determined by Log-
Rank test.
T-705 delayed-treatment study
While T-705 displayed remarkable efficacy when given
immediately after infection, an important question was whether
T-705 would be useful as a post-exposure intervention when
treatment was delayed. A second experiment was performed
whereby initiation of T-705 treatment was delayed by 12, 24, or
48 hpi (Fig. 1B). All rats received a dose of 20 pfu of RVFV by
aerosol exposure (approximately 10 LD50). All of the T-705-
treated rats received 100 mg/kg BID starting at the indicated time
points and continuing for 14 days. As expected, the RVFV-
infected, untreated rats succumbed to infection with MTD of
4.0+/20.3 days. Treatment with T-705 was remarkably effective
Favipiravir Protects from Lethal Rift Valley Fever
PLOS Neglected Tropical Diseases | www.plosntds.org 3 April 2014 | Volume 8 | Issue 4 | e2790
even when drug administration was delayed until 48 hpi (Fig. 1B).
All rats in the 1 hpi and 24 hpi groups survived. One rat (out of
12) in the 48 hpi group and two rats (out of 12) in the 12 hpi group
succumbed to infection with MTD of 9.7+/21.2 days. There was
no significant difference in survival times between any of the
T-705 treated groups, regardless of the time of initiation of
treatment, but all treated groups survived significantly longer than
the infected, untreated control rats (p,0.0001 by Log-Rank test
for comparison between each treated group and untreated
controls). Delaying T-705 treatment beyond 48 hpi was not
evaluated.
Clinical and virological assessment of rats treated with
T-705
Throughout the course of these studies, a total of 72 total rats
were infected with RVFV and treated with T-705 at various doses
and times post-infection, and only 6 succumbed to disease. The
remaining 66 rats (92%) survived this highly lethal infection with
no significant weight loss or fever (Fig. 2).
In both studies, the untreated RVFV-infected control rats lost
weight and developed fever within the last 24 hours before death
(Fig. 2, red lines). As expected based on our previous work [31],
these untreated rats had high viral loads in peripheral tissues,
including liver, spleen, and eye (Fig. 3, black circles). Virus-specific
antibody responses as measured by a total IgG ELISA showed that
the infected, untreated rats did not develop a detectable antibody
response prior to succumbing to the infection (Fig. 4).
The 66 surviving rats from all T-705-treated groups (regardless
of dose or time of treatment initiation) remained clinically healthy,
with minimal weight loss or fever, even after T-705 treatment was
removed (Fig. 2, black lines and data not shown). Surviving rats
had no detectable infectious virus (as measured by plaque assay) in
any tissues tested at necropsy (data not shown). Evidence of the
curtailed infection was confirmed by an indirect IgG ELISA, with
Figure 1. Survival of ZH501 RVFV-infected Wistar-Furth rats after treatment with T-705. (A) Results from T-705 dose-determination study.
Groups of 12 rats were infected with RVFV by aerosol exposure, with an average presented dose of 50 pfu/rat. Within 1 hour after infection, twice-
daily (BID) T-705 administration was given at the indicated doses. After 14 days (shaded area), drug treatment was removed, and the rats were
monitored for another 28 days, as indicated by the split x-axis. (B) Results from T-705 delayed-treatment study. Groups of 6–12 rats were infected by
aerosol exposure, with an average presented dose of 20 pfu/rat. All treated rats received 100 mg/kg of T-705 starting at the indicated times post-
infection and continuing for 14 days (shaded area), followed by an additional 28 days of monitoring for survival (split x-axis). For ease of visual
identification, the T-705 treatment period is indicated by gray shading from days 0–14 post-infection. For the delayed treatment groups, the
treatment periods are shifted by 12, 24, or 48 hours, which is not indicated on the graph. In both experiments, all groups of T-705 treated rats
survived significantly longer when compared to the untreated control rats (Log-Rank test p,0.0001).
doi:10.1371/journal.pntd.0002790.g001
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nearly all surviving rats displaying seroconversion at the time of
necropsy (Fig. 4A and B, black circles). Interestingly, in both
studies, several of the surviving rats treated with the highest dose of
T-705 (100 mg/kg) immediately after exposure (1 hpi) had IgG
antibody levels barely above the cutoff value, suggesting that T-
705 abated virus replication in these animals, thereby preventing
development of strong adaptive immune responses.
Within the dose-determination study (Fig. 4A), all 3 groups of T-
705 treated rats had significantly higher levels of total IgG
compared to the untreated control group (Fig. 4A, level of t-test
significance indicted by asterisks). There was an inverse correlation
between the average serum IgG titer and the dose of T-705
administered immediately after exposure (Fig. 4A). Rats given the
lowest dose of T-705 presented with the highest serum IgG titers,
whereas rats that received the highest dose of T-705 presented
with the lowest IgG levels. This suggests that as the drug dose
increased, less viral replication occurred and the antibody response
was diminished.
Figure 2. Weight loss and fever responses in Wistar-Furth rats treated with T-705. Results from the dose-determination study (A, C) and
the delayed-treatment study (B, D) are shown. For each graph, the shaded area represents the 14 days of T-705 treatment. The black lines represent
the mean +/2 SEM of the infected, treated surviving rats (n = 33 in A and C; n= 39 in B and D). The red line represents the mean +/2 SEM of the
infected, untreated control rats (n = 12 in A and C; n = 6 in B and D). Three rats from each experiment were infected, treated, and succumbed to
infection. Their weight loss and temperature data are plotted separately on each panel (blue, orange, and green lines). The x-axis is plotted through
day 16 only in order to make the earlier time points more clearly visible.
doi:10.1371/journal.pntd.0002790.g002
Figure 3. Tissue viral loads during T-705 efficacy studies in Wistar-Furth rats. Plaque assays were used to measure levels of infectious virus
within the indicated tissues. Data from both the dose-determination study and the delayed-treatment study are combined in this figure. The black
circles represent the tissue viral load from rats that were infected with RVFV but did not receive T-705 treatment (n = 6–12 per tissue; horizontal line is
the mean). For the T-705-treated rats, 92% survived (n = 66), and tissues taken at necropsy from the surviving rats did not have detectable tissue viral
loads by plaque assay (data not shown). A total of 6 T-705 treated rats from both studies died. The tissue viral loads from these 6 rats are shown as
individual data points (red stars; red horizontal line is the mean).
doi:10.1371/journal.pntd.0002790.g003
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For the delayed-treatment study, all 3 delayed groups had
significantly higher IgG levels compared to the untreated controls,
as indicated by the asterisks in Fig. 4B. There was also a
concomitant inverse correlation between serum IgG titers and
time of initiation of T-705 treatment (Fig. 4B). IgG titers were
highest when the drug was administered at 48 hpi. IgG titers
decreased as the treatment delay decreased, with several of the rats
treated immediately after exposure remaining at the cutoff value
(Fig. 4B).
The 6 treated rats that succumbed to infection over both studies
had a significantly longer MTD than their infected, untreated
counterparts (8.6+/20.76 and 4.4+/20.2 days, respectively when
combining data from both experiments; p,0.0001 by t-test). Most
of these 6 rats also displayed weight loss and all displayed body
temperature alterations that were not seen in the 66 treated
survivors (Fig. 2, individual data points). The delayed death in
these 6 rats was clinically associated with neurological signs such as
tremor, head-tilt, and circling in their cage. Typically, Wistar-
Furth rats succumb to RVFV infection prior to the development of
neurological signs; however there is evidence that a small
proportion of infected Wistar-Furth rats that survive beyond day
7 die of neurological disease [41], which is reminiscent of what is
seen in ACI and Lewis rats infected with RVFV [31]. Unlike the
infected untreated control rats, virus was found primarily within
the brain of these 6 treated rats that died with neurological signs,
with much lower levels in peripheral tissues and none detectable in
the blood at necropsy (Fig. 3, red stars). Blood samples were
available from 4 of these 6 rats, and all 4 rats had serum IgG levels
near the cutoff value (Fig. 4, red squares).
From a histological standpoint, infected, untreated control rats
displayed pathological changes primarily in the spleen and liver,
whereas the T-705 treated surviving rats had milder changes in
these 2 tissues (Table 1). The 6 T-705-treated rats that died had
very little pathology in the liver and spleen, but significant changes
in the brain in the form of meningitis and lymphocytic vasculitis,
which is concordant with the viral loads in the tissue (Fig. 3) and
our previous data from rats that died with neurological disease
[31].
Discussion
Broad-spectrum antivirals represent a gold-standard in the
development of effective countermeasures for treating a wide
range of viral diseases. The most well-known broad-spectrum
drug, Ribavirin, is currently FDA-approved to treat hepatitis C in
combination with interferon. Aerosolized ribavirin may be an
effective treatment for respiratory syncytial virus infections and as
an off-label use for treatment of hemorrhagic fever viruses such as
Lassa. Ribavirin has shown in vitro and in vivo activity against a
number of viruses, including RVFV, but success at treating
infected patients is mixed [42,43]. The clinical utility for the
treatment of RVF with Ribavirin has not been thoroughly tested
and is only recommended under compassionate use guidelines
[42,44–50]. Recent studies directly comparing Favipiravir activity
with Ribavirin suggest that Favipiravir is less toxic while having
equal or greater efficacy [8].
Wistar-Furth rats are very sensitive to RVFV when adminis-
tered subcutaneously or by aerosol [31,35–37,41]. Here, we
utilized an aerosol infection model which results in uniform
lethality from a fulminant hepatic disease within 4–6 days post
infection [31]. Clinical manifestations of this aerosol model include
fever, weight loss, porphyrin staining around the eyes/nose/
mouth, ruffled fur, and hunched posture. When Wistar-Furth rats
succumb to RVFV, virus is widespread in peripheral tissues,
including liver, spleen, kidney, lung, and heart. In the current
study, rats treated with T-705 survived infection with minimal
weight loss or fever, no detectable virus in the tissues at necropsy,
minimal tissue pathology, and measurable virus-specific antibody
responses. T-705 was able to abate virus replication enough that
the vast majority (92%) of rats survived infection without obvious
morbidity or mortality.
The small number of treated rats that died (6/72) developed
delayed-onset neurological disease as indicated by clinical signs,
Figure 4. IgG antibody responses during T-705 efficacy studies
in Wistar-Furth rats. Total IgG levels were measured using an indirect
antigen-capture ELISA, and the data are expressed as the SumOD of
each sample. The cutoff value is indicated by the horizontal dotted line,
which represents 3 standard-deviations above the control wells. (A)
Dose-determination study, and (B) Delayed-treatment study. For the
untreated groups on each panel, serum was taken at necropsy when
the rats were moribund (between 4–6 days post-infection). For the
surviving rats within the T-705 treated groups (black circles), serum
samples were taken at necropsy at the end of the study (day 42). Serum
was available for 4 of the 6 T-705 treated rats that died (indicated by the
red squares on each graph). Unpaired t-tests were used to compare
each T-705 treated group with the untreated control group. Level of
significance is indicated by the number of asterisks.
doi:10.1371/journal.pntd.0002790.g004
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pathology, and viral load in the brain tissue. Wistar-Furth rats
typically develop early-onset hepatic disease, although it has been
reported previously that vaccinated Wistar-Furth rats that
succumbed to aerosolized RVFV died later than expected with
encephalitic disease [41]. Similarly, mice that survive the early
hepatic form of disease after RVFV infection succumb to delayed-
onset neurologic disease [51–53]. The mechanism of neuroinva-
sion in inhalationally-exposed rats is under investigation, but work
with mice has shown that the olfactory bulb may play a critical
role [51,53], similar to what has been shown for other arboviruses
[54,55].
An aerosol infection model represents a stringent framework for
evaluation of novel therapeutics. Studies with mice have shown
that Ribavirin provides partial prophylactic protection from
subcutaneous infection with RVFV but no protection from aerosol
challenge [53]. This study highlights the need for antivirals that
will protect from aerosol exposure, which is the most likely method
for dispersal of a biological weapon [56]. Here we show that
Favipiravir (T-705) is remarkably effective at preventing disease
and death in Wistar-Furth rats exposed to aerosols of the virulent
ZH501 strain of RVFV.
There are a number of challenges to developing novel antiviral
therapeutics for emerging diseases and biodefense agents such as
Rift Valley Fever. In 2002, the FDA published the Animal Rule
which was designed to help respond to potential biological and
chemical threats for which efficacy trials in humans were neither
ethical nor logistically possible [57]. The Animal Rule states that
adequate and well-controlled animal trials can substitute for
human clinical trials in certain specific situations outlined in the
Animal Rule. To date, no antiviral drugs or vaccines have been
approved for human use solely based on the Animal Rule. As a
result of ongoing phase III efficacy trials for use of T-705 to treat
influenza, this drug is well-characterized for safety in humans.
Therefore it is possible that T-705 may be analogous to three
previous cases where drugs approved for separate indications
become approved for new indications through the use of the
Animal Rule [58–61]. Of these three drugs, one was a new clinical
indication for an already approved drug (pyridostigmine bromide
to treat soman nerve agent), the second for a drug approved in
Europe (hydroxocobalamin for cyanide poisoning), and the most
recent was for the use of a previously approved antibiotic,
levofloxacin, to treat pneumonic plaque [62]. The limitations of
the Animal Rule are well-described, and it is clear that it is not a
path to quick approval [58]. However, based on the 3 examples
cited above, obtaining a label-extension or new indication for an
already licensed drug is probably the most realistic route of
approval for drugs to treat emerging or highly pathogenic viruses.
The effectiveness of T-705 against RVFV and other viruses in
vitro and in vivo makes this novel drug a promising broad-spectrum
candidate. This study provides important preclinical proof-of-
concept data demonstrating that T-705 is efficacious in a stringent
rat model of lethal inhalational RVF even when treatment was
delayed 48 hours post-exposure. Further evaluation of the efficacy
of T-705 against the pathogenic strain of RVFV in a non-human
primate model is warranted. These findings are an encouraging
step forward and support the applicability of T-705 to treat
pathogenic viral agents other than influenza. Additional animal
studies with pathogenic strains of other medically important
viruses are warranted.
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